Trade Revance Therapeutics Inc - RVNC CFD
Add to favourite- Summary
- Historical Data
Spread | 0.05 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024929% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.002707% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 50.00% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 5.25 |
Open | 5.18 |
1-Year Change | -42.25% |
Day's Range | 5.12 - 5.25 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Oct 16, 2024 | 5.25 | 0.07 | 1.35% | 5.18 | 5.31 | 5.16 |
Oct 15, 2024 | 5.17 | 0.05 | 0.98% | 5.12 | 5.25 | 5.06 |
Oct 14, 2024 | 5.12 | -0.11 | -2.10% | 5.23 | 5.27 | 5.06 |
Oct 11, 2024 | 5.25 | 0.04 | 0.77% | 5.21 | 5.28 | 5.13 |
Oct 10, 2024 | 5.24 | 0.06 | 1.16% | 5.18 | 5.26 | 5.11 |
Oct 9, 2024 | 5.21 | 0.01 | 0.19% | 5.20 | 5.27 | 5.10 |
Oct 8, 2024 | 5.20 | -0.10 | -1.89% | 5.30 | 5.31 | 5.20 |
Oct 7, 2024 | 5.31 | 0.12 | 2.31% | 5.19 | 5.38 | 5.16 |
Oct 4, 2024 | 5.19 | -0.07 | -1.33% | 5.26 | 5.31 | 4.99 |
Oct 3, 2024 | 5.23 | 0.06 | 1.16% | 5.17 | 5.26 | 5.15 |
Oct 2, 2024 | 5.17 | 0.02 | 0.39% | 5.15 | 5.24 | 5.15 |
Oct 1, 2024 | 5.17 | -0.03 | -0.58% | 5.20 | 5.29 | 5.14 |
Sep 30, 2024 | 5.17 | -0.06 | -1.15% | 5.23 | 5.41 | 5.17 |
Sep 27, 2024 | 5.33 | -0.08 | -1.48% | 5.41 | 5.49 | 5.28 |
Sep 26, 2024 | 5.36 | 0.11 | 2.10% | 5.25 | 5.46 | 5.22 |
Sep 25, 2024 | 5.28 | -0.19 | -3.47% | 5.47 | 5.47 | 5.27 |
Sep 24, 2024 | 5.47 | 0.26 | 4.99% | 5.21 | 5.62 | 5.21 |
Sep 23, 2024 | 5.34 | 0.18 | 3.49% | 5.16 | 5.41 | 5.09 |
Sep 20, 2024 | 5.80 | 0.04 | 0.69% | 5.76 | 5.88 | 5.72 |
Sep 19, 2024 | 5.83 | -0.17 | -2.83% | 6.00 | 6.01 | 5.70 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Revance The Company profile
About Revance Therapeutics Inc
Revance Therapeutics, Inc. is a commercial stage biotechnology company. The Company is focused on advanced aesthetic and therapeutic offerings, including neuromodulator product, DaxibotulinumtoxinA for Injection. The DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a purified botulinum toxin that does not contain human or animal-based components. The Company is also evaluating additional aesthetic and therapeutic indications for DaxibotulinumtoxinA for Injection including the full upper face, which includes glabellar lines, forehead lines and crow’s feet, and adult upper limb spasticity. It offers products and services for United States aesthetics practices, including the resilient hyaluronic acid (RHA) Collection of dermal fillers and OPUL. The RHA Collection of dermal fillers is a dermal filler for the correction of dynamic facial wrinkles and folds. OPUL’s product offering includes the point-of-sale platform, software and hardware terminal.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Revance Therapeutics Inc revenues increased from $15.3M to $77.8M. Net loss increased less than 1% to $281.3M. Revenues reflect Product Segment increase from $14.9M to $76.5M, Service Segment increase from $417K to $1.3M. Net loss reflects Research & Development balance decrease of 11% to $99.4M (expense), Interest expense decrease of 59% to $6.3M (expense).
Industry: | Biopharmaceuticals |
1222 Demonbreun Street
Suite 2000
NASHVILLE
TENNESSEE 37203
US
News
US earnings seasons off to a solid start as focus shifts to tech giants
The US earnings season has started on a positive note, with major banks exceeding expectations and boosting market sentiment.Key themes for the sector include investments in artificial intelligence, capital expenditure returns, and consumer trends in advertising and e-commerce. The S&P 500 continues to climb, driven by strong earnings, resilient economic growth, and the potential for interest rate cuts. Keep an eye on significant support and resistance levels as the market tests new record highs.
14:31, 17 October 2024ECB Preview: cooling growth and inflation call for another rate cut
Markets are convinced the European Central Bank (ECB) will cut rates by 25 basis points again at Thursday’s meeting.
12:41, 16 October 2024Australian labour force data forecast to reveal stable jobs market
Australia's labour market remained stable in September 2024, with the unemployment rate forecast to hold at 4.2%, supported by a 25,200 person rise in employment. Despite the economy teetering on the edge of recession, strong hiring trends persist, challenging market economists' predictions.
07:41, 15 October 2024Applying fundamental and technical strategies to Gold Trading
Last week, we visualised the key potential drivers of gold in a chart focused on recent performance. Understanding the factors that can move gold prices is essential, but translating that knowledge into effective trading strategies is where the real potential can lie.
08:00, 14 October 2024S&P 500 expected to deliver modest earnings growth in Q3
Earnings growth across the S&P 500 is expected to be modest in Q3, with a projected 4.2% increase in EPS, down from 7.8% in the previous quarter. Information technology, health care, and communication services are poised to drive growth, particularly IT with a forecasted 15% year-over-year EPS increase.
12:40, 11 October 2024US Core CPI tipped to remain unchanged in September
US inflation expectations are steady, with core CPI projected to remain at 3.2% for September while headline inflation moderates to its lowest level since February 2021. Despite the US Federal Reserve delivering a 50 basis point interest rate cut in September, stronger-than-expected job market data has raised concerns about sustained economic demand and inflation pressures.
07:10, 9 October 2024RBNZ expected to deliver “jumbo” rate cut
The Reserve Bank of New Zealand is set to cut interest rates during its upcoming meeting, with expectations of either a 25 or 50 basis point reduction. This move follows a 25 basis point cut in August as the RBNZ responded to the country’s recessionary conditions and inflation concerns.
08:48, 8 October 2024People also watch
Still looking for a broker you can trust?
Join the 650,000+ traders worldwide that chose to trade with Capital.com